VIDEO: Circulating tumor DNA levels could help predict hepatocellular carcinoma recurrence

ByDavid Statman

In this video, Thomas Marron, MD, PhD, discussed data he presented on patients with liver cancer treated with neoadjuvant cemiplimab (Libtayo, Regeneron) at American Association for Cancer Research Annual Meeting.

Marron, an associate professor of medicine at Icahn School of Medicine at Mount Sinai, discussed how his study fits into the larger picture of liver cancer treatment, where relatively few neoadjuvant studies have been done in the immunotherapy era.

“This was a very small study, but it’s the first bit of data we have in HCC showing that we may be able to use pre-op and post-op circulating tumor DNA levels to help predict who’s going to recur,” Marron said.

Published by:

Sources/Disclosures

Collapse

Disclosures: Marron reports serving on advisory and/or data safety monitoring boards for and/or research grants from AbbVie, Arcus, Astellas, AstraZeneca, Atara, Boehringer Ingelheim, Bristol Meyers Squibb, Celldex, Chimeric, DBV Technologies, G1 Therapeutics, Genentech, Glenmark, Merck, NGMbio, Regeneron, Rockefeller University, Simcere and Surface.

Take Homes from AACR

Read more

VIDEO: Circulating tumor DNA levels could help predict hepatocellular carcinoma recurrence

Related Content